-
Could Microbiome Changes Explain Rise in Colon Cancer Among the Young?
With colon cancer on the rise among younger Americans, researchers are working to figure out why. A new study suggests the microbiome — the community of microorganisms in the body — may play a role.
Category: News
-
New bacterial clues about why young people are getting colorectal cancer
The type of bacteria, fungi, and viruses in colorectal cancer tumors varies significantly between younger and older patients, offering a clue toward understanding why cases are rising in people under 45, according to a study due to be presented at next week’s American Society of Clinical Oncology annual meeting.
Category: News
-
Types of Bacteria Vary Widely in Tumors of People with Early vs. Late-Onset Colorectal Cancer
Researchers at Georgetown University’s Lombardi Comprehensive Cancer Center studied the microbiome of people with colorectal cancer and found the makeup of the bacteria, fungi and viruses in a person’s tumor varied significantly depending on whether they were diagnosed with early onset disease (age 45 or younger) or late-onset disease (age 65 or older).
Category: News
-
Continued Development of Targeted Therapies Aims to Address Unmet Needs in CRC
John L. Marshall, MD, discusses the identification of targetable subsets of patients with advanced CRC, unmet needs that remain to be addressed for patients with advanced CRC, and the continued need for a multidisciplinary approach in treating patients across the gastrointestinal cancer spectrum.
Category: News
-
Key Takeaways from 2023 SOGO
John L. Marshall, M.D., discusses the key takeaways from the 8th Annual School of Gastrointestinal Oncology® (SOGO) and remaining unmet needs for patients with metastatic colorectal cancer (CRC).
Category: News
-
Dr. Marshall Highlights 2023 ASCO Gastrointestinal Cancers Symposium Research
Dr. Marshall discusses the significant and exciting GI Cancer research presented at the 2023 ASCO GI Cancer Symposium.
Category: News
-
Colorectal Cancer in Young People
Dr. John L. Marshall discusses the increasing incidence rates for colorectal cancer in people under the age of 50.
Category: News
-
Nivolumab Plus Cabozantinib Shows Early Promise in Advanced HCC
Dr. Aiwu He discusses early results from her research0- CheckMate 040, nivolumab plus cabozantinib with or without ipilimumab- which showed good clinical activity and survival.
Category: News
-
Antibiotics Can Be Used During Durvalumab Treatment in Biliary Cancer
“People with advanced BTC can safely be treated with antibiotics while benefiting from treatment with durvalumab plus chemotherapy,” lead author Aiwu He, MD, PhD.
Category: News
-
Engineer Credits Proton Therapy with Beating Stomach Cancer
“They have a great team approach at MedStar Georgetown with an oncologist, surgeon, and radiation therapist,” explains Jack. They told me that because of where my tumor was, I was a great candidate for proton therapy instead of standard radiation.”
Category: News